AGK7 (Synonyms: SIRT2 Inhibitor (Inactive Control)) |
Catalog No.GC15931
One-Click Copy Product Info
|
cell-permeable, selective inhibitor of SIRT2
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 304896-21-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
AGK7 is an inactive control of AGK2, a cell-permeable and selective SIRT2 inhibitor [1][2].
The sirtuins are members of the histone deacetylase family of proteins that participate in many cellular functions and play an important role in aging. Silent information regulator 2 (Sir2) is a nicotinamide adenine dinucleotide-dependent histone deacetylase (HDAC) in yeast that participates in cell protection and cell cycle regulation. Human SIRT2 is involved in cell cycle regulation through the deacetylation ofα-tubulin [1].
AGK7 is an inactive control of AGK2 to be used in experiments with AGK2. AGK2 is a cell-permeable, potent and selective SIRT2 inhibitor with IC50 value of 3.5 μM. AGK2 slightly inhibited SIRT1 and 3 only at concentrations over 40 μM. Relative to an inactive control AGK7, AGK2 increased acetylated tubulin. In H4 cells transfected with α-Syn, AGK2 reduced α-Syn-mediated toxicity in a dose-dependent way. By contrast, the inactive AGK7 had no effect. In H4 cells cotransfected withα-Syn and synphilin-1, the inactive AGK7 failed to affect a-Syn aggregation, whereas AGK2 promoted the formation of enlarged inclusions [1].
References:
[1]. Outeiro TF, Kontopoulos E, Altmann SM, et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science. 2007 Jul 27;317(5837):516-9.
[2]. Cole PA. Chemical probes for histone-modifying enzymes. Nat Chem Biol. 2008 Oct;4(10):590-7.
| Cas No. | 304896-21-7 | SDF | |
| Synonyms | SIRT2 Inhibitor (Inactive Control) | ||
| Chemical Name | 2-cyano-3-[5-(2,5-dichlorophenyl)-2-furanyl]-N-8-quinolinyl-2-propenamide | ||
| Canonical SMILES | O=C(/C(C#N)=C/C1=CC=C(C2=CC(Cl)=CC=C2Cl)O1)NC3=CC=CC4=C3N=CC=C4 | ||
| Formula | C23H13Cl2N3O2 | M.Wt | 434.3 |
| Solubility | ≤0.5mg/ml in DMSO;0.2mg/ml in dimethyl formamide | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3026 mL | 11.5128 mL | 23.0256 mL |
| 5 mM | 460.5 μL | 2.3026 mL | 4.6051 mL |
| 10 mM | 230.3 μL | 1.1513 mL | 2.3026 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 31 reference(s) in Google Scholar.)